Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974652 | 0.84 | TRPV4 (0.58) | TRPV4MEN1KMT2ATTRALB | |
| SCHEMBL425826 | 0.78 | TRPV4 (0.46) | TRPV4MEN1KMT2ATTRALB | |
| SCHEMBL20472327 | 0.78 | TRPV4 (0.46) | TRPV4ESR1ESR2MEN1KMT2A | |
| SCHEMBL15674088 | 0.75 | TRPV4 (0.43) | TRPV4MEN1KMT2AKDM4ECYP11B1 | |
| SCHEMBL31113834 | 0.75 | TRPV4 (0.43) | TRPV4MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL13868306 | 0.75 | TRPV4 (0.43) | TRPV4MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL18305809 | 0.75 | TRPV4 (0.43) | TRPV4MEN1KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL423554 | 0.75 | TRPV4 (0.43) | TRPV4TTRALBCYP11B1CYP11B2 | |
| SCHEMBL31287347 | 0.75 | UPP1 (0.43) | MEN1KMT2ATTRALBCYP3A4 | |
| SCHEMBL14601371 | 0.75 | SELL (0.46) | TRPV4ESR1ESR2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4663635-A1 | CRYSTALLINE FORM OF SULFONAMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250179093-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| WO-2025077774-A1 | AT2R ANTAGONIST AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2025-04-17 | — | — | WO | disclosed |
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| CN-119798233-A | AT2R antagonist and application thereof | 武汉人福创新药物研发中心有限公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2022152233-A1 | KRAS G12C INHIBITORS | BEIGENE, LTD. (KY) | 2022-07-21 | — | — | WO | disclosed |
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179093-A1 | KRAS MODULATORS | KRAS, NRAS, HRAS | TRPV4 4780/4885ESR1 1874/4885ESR2 2095/4885 |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | TRPV4 4420/4885ESR1 1794/4885ESR2 3073/4885 |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | TRPV4 4420/4885ESR1 1794/4885ESR2 3073/4885 |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | TRPV4 3413/4885ESR1 1734/4885ESR2 3245/4885 |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | TRPV4 4420/4885ESR1 1794/4885ESR2 3073/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | TRPV4 4749/4885ESR1 1342/4885ESR2 858/4885 |
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SULT2A1, KAT8, TST | TRPV4 4216/4885ESR1 4376/4885ESR2 4254/4885 |
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | TRPV4 4752/4885ESR1 3365/4885ESR2 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.